AXNX News and Press, Axonics Modulation Technologies Inc. From 07/01/20

The FDA has approved Axonics Modulation Technologies' (NASDAQ: AXNX ) supplemental marketing application for 3T full-body magnetic resonance imaging (MRI) conditional labeling for the Axonics r-SNM System. More news on: Axonics Modulation Technologies, Inc., Healthcare stocks news, Stock...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that it has received U.S. Food & Drug Adm...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

Under a premarket approval supplement, the FDA has approved Axonics Modulation Technologies' (NASDAQ: AXNX ) new wireless patient Remote Control with SmartMRI technology for the Axonics r-SNM System. More news on: Axonics Modulation Technologies, Inc., Healthcare stocks news, ...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced U.S. Food & Drug Administration (FDA) app...

Company Announces U.S. Registry Study to Advance Understanding of Treatment Patterns and Outcomes Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“S...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today...

Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...

Axonics Modulation Technologies, Inc. (AXNX) Q1 2020 Earnings Conference Call May 05, 2020 04:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Particip...

Axonics Modulation Technologies (NASDAQ: AXNX ) prices public offering of 4M common shares at $32.50, yielding gross proceeds of ~$130M. More news on: Axonics Modulation Technologies, Inc., , Tech stocks news, Read more ...